Trial · NCT02145468
Results by group110
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 110
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12 | Placebo | First occurence of MACE | 123 | Participants | |
| Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12 | Losmapimod 7.5 mg BID | First occurence of MACE | 139 | Participants | |
| Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12 | Placebo | CV Death | 34 | Participants | |
| Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12 | Losmapimod 7.5 mg BID | CV Death | 31 | Participants | |
| Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12 | Placebo | MI | 74 | Participants | |
| Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12 | Losmapimod 7.5 mg BID | MI | 90 | Participants | |
| Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12 | Placebo | SRI-UR | 15 | Participants | |
| Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12 | Losmapimod 7.5 mg BID | SRI-UR | 18 | Participants | |
| Number of Participants With First Occurrence of MACE Through Week 24 | Placebo | First occurrence of MACE | 162 | Participants | |
| Number of Participants With First Occurrence of MACE Through Week 24 | Losmapimod 7.5 mg BID | First occurrence of MACE | 176 | Participants | |
| Number of Participants With First Occurrence of MACE Through Week 24 | Placebo | CV Death | 45 | Participants | |
| Number of Participants With First Occurrence of MACE Through Week 24 | Losmapimod 7.5 mg BID | CV Death | 38 | Participants | |
| Number of Participants With First Occurrence of MACE Through Week 24 | Placebo | MI | 98 | Participants | |
| Number of Participants With First Occurrence of MACE Through Week 24 | Losmapimod 7.5 mg BID | MI | 117 | Participants | |
| Number of Participants With First Occurrence of MACE Through Week 24 | Placebo | SRI-UR | 19 | Participants | |
| Number of Participants With First Occurrence of MACE Through Week 24 | Losmapimod 7.5 mg BID | SRI-UR | 21 | Participants | |
| Number of Participants With First Occurrence of the Composite of CV Death or MI up to Week 12 and Week 24 | Placebo | Week 12 | 110 | Participants | |
| Number of Participants With First Occurrence of the Composite of CV Death or MI up to Week 12 and Week 24 | Losmapimod 7.5 mg BID | Week 12 | 122 | Participants | |
| Number of Participants With First Occurrence of the Composite of CV Death or MI up to Week 12 and Week 24 | Placebo | Week 24 | 145 | Participants | |
| Number of Participants With First Occurrence of the Composite of CV Death or MI up to Week 12 and Week 24 | Losmapimod 7.5 mg BID | Week 24 | 156 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02145468/results